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Abstract
Purpose The number of antidepressants prescribed in the
UK has been increasing over the last 25 years; however,
the reasons for this are not clear. This study examined
trends in antidepressant prescribing in the UK between
1995 and 2011 according to age, sex, and drug class, and
investigated reasons for the increase in prescribing over
this period.
Methods This is a retrospective analysis of antidepressant
prescribing data from the Clinical Practice Research
Datalink: a large, anonymised, primary care database in the
UK. The dataset used in this study included 138 practices,
at which a total of 1,524,201 eligible patients were regis-
tered across the 17-year period. The proportion of patients
who received at least one antidepressant prescription and
the number of patients who started a course of antide-
pressants were calculated for each year of the study. We
used person years (PY) at risk as the denominator. The
duration of treatment for those starting antidepressants was
also examined.
Results 23% of patients were prescribed an antidepressant
on at least one occasion over the 17-year study period.
Antidepressant prescriptions rose from 61.9 per 1000 PY in
1995 to 129.9 per 1000 PY in 2011. This was largely dri-
ven by an increase in prescribing of selective serotonin
reuptake inhibitors and ‘other’ antidepressants. In contrast,
incidence rates of those starting antidepressants remained
relatively stable (1995: 21.3 per 1000 PY; 2011: 17.9 per
1000 PY). The duration of treatment increased with later
starting years, with an increasing proportion of long-term
use, and decrease in short-term use.
Conclusion The increase in antidepressant prescribing
over the study period appears to be driven by an increase in
long-term use of these medications.
Keywords Antidepressants  General practice 
Prescribing  Trends  Primary care
Introduction
In the UK, antidepressant (AD) prescribing has increased
substantiality over the past two decades, leading to con-
cerns that they are being overprescribed. Similar increases
have been reported in other European countries, the USA,
Canada, and Australia [1–10]. There are a number of
potential explanations for this rise, including improved
recognition of depression, availability of new AD drugs,
changes in patient/GP attitudes, and a broadening of the
range of indications treated with ADs.
One particularly important question is whether the rise
in AD prescribing can be attributed to more people starting
on AD treatment. Previous studies that have investigated
this issue have produced conflicting results, with some
studies finding an increase in the number of people who
have started taking ADs, and other studies finding that rates
have remained stable, or even decreased [2, 4, 6, 8, 10–12].
There is also increasing evidence to suggest that the rise in
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AD prescribing is driven by an increase in long-term use
[2, 4, 6–8, 12].
Existing studies investigating AD trends in the UK have
often been restricted to specific regions [4, 13], spanned
short-time periods, or have limited their analysis to patients
with a diagnosis of depression [11, 12]. ADs are prescribed
for a wide range of indications, and research suggests that a
substantial proportion of patients prescribed them do not
have a diagnosis of depression [14, 15]. To gain a more
complete understanding of AD trends, it is, therefore,
necessary to broaden analysis beyond patients with a
depression diagnosis. Moreover, as GPs increasingly clas-
sify depression using symptom codes as opposed to diag-
nostic codes [16–18], restricting analysis to patients with a
diagnosis may miss cases.
This paper examines trends in AD prescribing (regard-
less of indication) between 1995 and 2011 using data from
the Clinical Practice Research Datalink (CPRD): a large,
anonymised, primary care database in the UK. Our objec-
tives were to:
• Examine trends in incidence (the number of patients
starting on ADs) and period prevalence (patients
starting ADs plus existing AD users) over the study
period, and investigate whether there are differences
according to age, gender, and drug class.
• Examine trends in the duration of treatment amongst
patients starting ADs.
• Explore the potential influence of external events that
overlapped with our study period, including (1) the
2008 recession; (2) the 2006 quality outcomes frame-
work (QOF); (3) the 2003 Medicines and Healthcare
products Regulatory Agency (MHRA) advice against
the use of selective serotonin reuptake inhibitors
(SSRIs) other than fluoxetine in under 18s and (4) the
introduction of the ‘Improving Access to Psychological
Therapies’ (IAPT) initiative in 2006.
Methods
Data source
The Clinical Practice Research Datalink (CPRD) is one of
the largest primary care databases in the world and contains
anonymised electronic records from over 4 million active
patients, representing 6.9% of the UK population (http://
www.cprd.com). The CPRD contains information on diag-
nosis, symptoms, prescriptions, referrals and test results, as
well as demographic and administrative information. These
data are routinely entered by GPs and their staff onto their
computer systems. Participating general practices use a
computerised system called Vision, which has built-in
software to extract and anonymise data from practice com-
puters. The patient population captured in the database is
broadly representative of the overall UK population in terms
of age, sex and geographical distribution [19, 20].
Study population
We examined trends in AD prescriptions issued in Primary
Care between 1995 and 2011. We included all patients
aged 14 and over who had been registered with a CPRD
practice for at least 3 years; therefore, data were extracted
from 1st January 1992. Analyses were restricted to ‘ac-
ceptable’ patient records from practices that met the CPRD
quality criteria and contributed data for the entire study
period. The dataset used in this study included 138 prac-
tices, at which a total of 1,524,201 eligible patients were
registered across the 17-year period.
Patients under 14 years were excluded as AD prescrib-
ing is rare in younger children. A minimum period of
3 years registration was chosen to improve the identifica-
tion of patients who started ADs (referred to as incident
cases) Incident AD users were defined as those with no
previous AD prescription during the study period and all
incident cases had a minimum AD-free period of 3 years.
For example, a patient prescribed an AD in July 2000
would have to be registered since at least July 1997 to be
included in the year 2000 stats. If they had no prior pre-
scriptions during the study period, they would be classified
as an incident case for that year.
Analysis
We identified all AD prescriptions (drugs included in
‘‘Comparison with existing literature’’ of the British
National Formulary) [21] prescribed to patients between 1st
January 1992 and 31st December 2011. These prescriptions
were classified into three categories, based on their proposed
method of action (Electronic Supplementary Material 1):
selective serotonin reuptake inhibitors (SSRIs), tricyclic
antidepressants (TCAs), and ‘other’ antidepressants, largely
consisting of mirtazapine and venlafaxine (78%).
For each calendar year of the study, we calculated the
number of patients who received at least one AD pre-
scription, and the number of patients who started ADs. We
used person years at risk (PY) as the denominator; for
example, a patient who was registered for 3 months of the
year and then left the practice (e.g. died, or transferred to a
non CPRD-contributing practice) would contribute
0.25 years to the denominator for that year. Trends in AD
prescribing were also examined separately by drug class
and stratified according to age and sex.
Join point regression analysis [22] was used to estimate
the years (with 95% CI) in which changes in trends
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occurred (software version 4.2. available from http://sur
veillance.cancer.gov/joinpoint/). The analysis involves fit-
ting a series of joined straight lines, and selecting the
point(s) at which the rate of increase/decrease changes
significantly (join points). An annual percentage change
(APC) is calculated for each of the identified trends, based
on the slope of the line segment between join points.
Sensitivity analyses were conducted (1) excluding patients
prescribed low doses (\75 mg) of amitriptyline, as this is
commonly prescribed for indications other than depression,
particularly pain [3, 5] and (2) amongst the subgroup of
patients with a diagnosis of depression during the study period
(see Electronic Supplementary Material 2 for a list of read
codes [23] used to indicate a depression diagnosis).
To examine changes in long-term prescribing over time,
we calculated the duration of incident treatment episodes.
The intended duration of treatment was estimated from the
dosing instructions and the quantity prescribed. Where no
dosage instructions were provided, the median for the
product type was used. Consecutive prescriptions were
considered to be part of the same treatment episode if the
gap between the expected end of one prescription and the
start of another was less than 4 months. This was based on
guidance from the ACNP task force [24] who suggest
recovery is ascribed after at least 4 months following the
onset of remission. Prescription duration was divided into
the following six categories: B30, 31–60, 61–180,
181–365, 366–730, 731 days?. Consecutive prescriptions
were not required to be the same product type. We use the
phrase ‘long-term use’ to refer to prescriptions with a
duration greater than 1 year.
Results
There were 1,280,995 antidepressant prescribing events
amongst 350,398 patients (23% of the total sample). The
majority of the AD prescriptions were SSRIs (51%), with
TCAs accounting for 40% and other ADs 9%. The number
of patients who started ADs over the study period was
241,903.
Prevalence of antidepressant usage
Figure 1 illustrates the period prevalence of antidepressant
use per 1000 PY for each year of the study. AD prescriptions
increased by more than 100%, rising from 61.9 per 1000 PY
in 1995 to 129.9 per 1000 PY in 2011. In the join point
analysis, the best fitting model included the following four
join points (Supplementary Figure 1): 1997 (95% CI
1997–2000) when there was a reduction in the rate of
increase in AD prescribing, 2002 (95% CI 2000–2003) after
which AD prescribing levelled off, 2005 (95% CI
2004–2006) when prescribing rose again, and 2008 (95% CI
2007–2009) when the rate of prescribing accelerated. A
similar pattern was observed for males and females, although
AD prescribing was about two times greater in females.
There was a progressive increase in the level of AD
prescribing with increasing age (Fig. 2). The overall pat-
tern of change between 1995 and 2011 was similar across
the age strata, with the exception of the youngest age
category (\18’s). For this group, we found a substantial
drop in prevalence between 2002 and 2006, following
which there was a steady increase (see inset in Fig. 2).
There was also a notable drop in prevalence between 2002
and 2006 in the 18–30-year age group (from 66.5 to 58.3
per 1000 PY).
Figure 3 shows prevalence according to drug class. The
increase in AD prescriptions was driven largely by a rise in
prescriptions of SSRIs and ‘other’ ADs. In contrast, TCA
prescriptions (56% amitriptyline) remained relatively stable.
Incidence of antidepressant usage
Figure 4 illustrates the number of patients starting ADs for
the first time per 1000 PY for each year of the study. In
contrast to the substantial rise in prevalence of AD use, the
number of new cases has fallen slightly over time, from
21.3 per 1000 PY in 1995 to 17.9 per 1000 PY in 2011. The
best fitting model included two join points; one in 2002
(95% CI 1999–2003), after which there was a substantial
decline in incidence rates, and one in 2005 (95% CI
2004–2007) when incidence rates began to increase (Sup-
plementary Figure 2). The overall pattern was similar for
males and females (Supplementary Figure 3). Incidence
rates remained higher in females throughout the study;
however, the difference became less pronounced over time
(the F:M ratio decreased from 1.9:1 in 1995 to 1.2:1 in
2011. Chi-square test of trend: P =\0.001).
The pattern of prescribing was found to differ according
to AD drug class (Supplementary Figure 4). Incident pre-
scribing of SSRIs increased between 1995 and 2001,
whereas TCAs declined over this period. Incidence rates
for other AD prescriptions remained relatively
stable throughout the study period.
Duration of incident prescriptions
We examined trends in the duration of treatment for
patients starting ADs between 1995 and 2009. The
median length of treatment increased over this period,
from 44 to 56 days. Figure 5 shows the proportion of
patients with different treatment lengths for each year of
the study. We found an increasing proportion of long-
term use with later starting years, and a corresponding
decrease in short-term use.
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Further information on treatment duration trends is
provided in Supplementary Table 1, where results are
presented separately according to drug class. For SSRIs
and other AD prescriptions, the pattern of results was the
same as for all ADs. For TCAs, there was an overall
reduction in the length of treatment with later starting
years; however, the proportion of patients prescribed TCAs
for 2 years or more also increased slightly.
Sensitivity analysis
Excluding patients prescribed low-dose amitriptyline
When excluding patients with low doses of amitriptyline
(\75 mg) overall trends for prevalence and incidence
(Supplementary Figures 5a and 5b) are similar to the main
analysis. However, for TCAs, there was a substantial drop
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in prevalence and incidence rates over time, such that in
later years, this drug class accounted for very few AD
prescriptions.
Amongst the subgroup with depression
When restricting the sample to those with a diagnosis of
depression (67% of patients prescribed an AD), a similar
pattern of results was found to the main analysis. However,
the drop in incidence of TCAs was more marked (Sup-
plementary Figures 6a and 6b).
Discussion
Summary
Nearly a quarter of patients in the sample were prescribed
an AD on at least one occasion during the study period.
The prevalence of AD prescribing doubled between 1995
and 2011, although levels remained relatively stable be-
tween 2002 and 2005, when there was a notable reduction
in prescribing to those under 30 years. The overall rise in
prescribing was largely driven by an increase in SSRIs and
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other ADs. Our findings suggest the observed rise in pre-
scribing is not due to an increased number of people
starting meditation, but rather appears to be explained by
an increase in the duration of treatment.
Strengths and limitations
The study included data from a large anonymised data-
base of Primary Care Patients, which enabled examination
of AD trends according to drug class, and also by age and
gender. Trends were also examined over a long period of
time (17 years). We examined AD prescribing regardless
of indication, which is important, given that ADs are
prescribed for a range of indications other than depres-
sion; only 67% of the patients in our study had a
depression-related Read code, and only 39% of patients
who started on AD had one recorded in the year prior to
their first prescription. Sensitivity analysis conducted in
the subgroup of patients with depression and excluding
those prescribed low doses of amitriptyline found similar
results.
Findings must also be interpreted in light of several
limitations. First, our analysis is based on prescriptions
issued in Primary Care only, and we do not have infor-
mation about the dispensing of medications or patient
compliance. Second, although trends were examined over a
long period of time, data were only available until 2011.
Third, the results may not generalise to practices that do
not contribute to the CPRD, or to other countries which
have different healthcare systems. Fourth, when calculating
duration of treatment, we chose a minimum period of
4 months between prescriptions to indicate the end of a
treatment episode. However, we are unable to say whether
patients actually achieved remission during the treatment
period. Findings from sensitivity analysis using a minimum
duration of 30 days and 6 months were similar (results
available on request). Finally, incident AD users were
defined as those with no previous AD prescription during
the study period. This may have led to a bias of selecting
proportionally more ‘real’ new starters and fewer re-star-
ters in the later part of the follow-up period.
Comparison with existing literature
The rise in prevalence of AD prescriptions found in this
study is consistent with existing literature [1–10]. Studies
regarding trends in incidence have been less consistent,
with some studies reporting an increase in incident pre-
scriptions over time [4, 6, 8], and others finding stable rates
or a decrease [2, 10–12]. Our findings are also in line with
previous reports that the rise in AD prescribing is due to an
increase in the proportion of patients receiving long-term
treatment [2, 4, 6–8, 12]. For example, a previous study
using this database [11] found that the increase in AD
prescriptions between 1993 and 2005 was explained by an
increase in the proportion of patients receiving long-term
prescriptions. Another UK study examining prescribing
rates between 2003 and 2013 [12] found a reduction in AD
prescribing for incident depression, and an increase in
prescribing for recurrent depression. We extend these
studies by examining trends over a longer time period,
which overlaps with several important external events, and
by not limiting our analysis to those with depression.
Examining prescribing trends in the whole population is
important, as a large proportion of patients prescribed ADs
do not have a depression diagnosis. Moreover, GPs
increasingly use symptom rather than diagnostic codes
[16–18], which could result in cases being missed. There is
also evidence to suggest that the introduction of QOF
performance indicators for depression may have influenced
prescribing [12]. This was found to be the case for both
genders, and for both younger and older adults [12].
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The prevalence and incidence of AD prescriptions was
consistently higher amongst females than males. Although, as
found in some previous studies [25, 26] there was a decrease in
the ratio of female to male prescribing over time, indicating
that AD prescribing has increased more in males. This could
suggest there has been an increase in help-seeking behaviour
in males, an increase in depression, or an increase in the
number of males prescribed an AD for other indications.
The limited evidence on AD trends according to age
suggests that AD prescriptions increase with increasing
patient age [26–28]. We found an increase in prevalence of
AD for all age groups, with the exception of those under
18 years [4, 5, 26]. Antidepressant prescribing in adoles-
cents has received considerable attention following MHRA
advice in 2003 against the initiation of SSRIs except flu-
oxetine in this age group. Consistent with our findings,
studies from Europe, USA and Australia show that the
regulatory warnings were associated with a reduction in the
prescribing of ADs to children and adolescents [17, 29–33].
Our data also suggest that the warnings had a spill-over
effect into other age groups [34, 35], with a join point
indicating a change in trend in 2002. Several studies have
found the reduction in AD prescribing following the reg-
ulatory warnings was not associated with a rise in adoles-
cent suicides or non-fatal self-harm [31, 36, 37]. Rates
began to rise following a second join point in 2005, which
could suggest that concerns about a possible increased risk
of suicidality have reduced.
We also explored whether trends in AD use were
affected by a number of other events overlapping with the
study period. These included the introduction of QOF
performance indicators for depression in 2006, the 2008
recession, and improved access to cognitive behavioural
therapy (CBT) through the IAPT initiative in 2006. Some
studies have found an increase in AD prescribing or
depression following the recession [18, 38]. For example,
Kendrick et al. [18] found a rise in the prevalence of
depression after 2008 in younger men, associated with
increased unemployment. In this study, we found the best
fitting model for trends in AD prevalence included a join
point at 2008, following which the rate of prescribing
accelerated. However, unlike Kendrick et al., our data
suggest there was an increase in prevalence for both males
and females, and for all age groups. Similar to previous
research, we found no relationship between trends in AD
prescribing and the introduction of IAPT services [38, 39],
although it is possible that IAPT availability may have
attenuated the recent rise in incident prescribing.
Implications for research and practice
Guidelines for depression recommend that patients con-
tinue medication for at least 6 months after remission to
reduce the risk of relapse [40]. Our findings of longer
treatment periods for patients who began taking ADs in
later years of the study suggest there is improved adher-
ence to practice guidelines. While encouraging, it is
important to note that the majority (65%) of patients who
began AD treatment in 2009 discontinued treatment
before the recommended time, with 32% of patients being
prescribed ADs for 30 days or less. The increase in
duration could also be attributed to the introduction of
newer ADs, which may be better tolerated, or to changes
in patient/GP attitudes regarding the treatment of mental
illness. Alternatively, it could reflect failure by GPs to
adequately follow-up patients and monitor treatment, with
several studies finding that many patients on long-term
AD treatment have not had a recent medication review
[28, 41].
While long-term prescribing may be appropriate for
some patients, currently little is known about the risks and
benefits of taking AD medication long term. In the future,
research, guidelines, and performance indicators should
focus more on the appropriateness of long-term prescrib-
ing, and ensure regular review of patients who become
established on long-term treatments.
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